Insider Buying: Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Purchases 55,256 Shares of Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan acquired 55,256 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the purchase, the director now owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. The trade was a 0.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pulse Biosciences Trading Up 0.4 %

PLSE opened at $19.24 on Wednesday. Pulse Biosciences, Inc. has a 1-year low of $6.59 and a 1-year high of $22.69. The firm’s 50 day simple moving average is $17.74 and its two-hundred day simple moving average is $16.50.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the firm earned ($0.19) EPS.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of PLSE. Price T Rowe Associates Inc. MD purchased a new stake in shares of Pulse Biosciences during the first quarter worth $88,000. Quest Partners LLC acquired a new position in Pulse Biosciences in the 2nd quarter valued at $91,000. Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences in the first quarter valued at approximately $109,000. Rhumbline Advisers raised its holdings in Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after purchasing an additional 1,608 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new position in Pulse Biosciences during the third quarter worth about $378,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.